Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

81. Allergy and COVID-19 Vaccination - Guide for health professionals

Allergy and COVID-19 Vaccination - Guide for health professionals Guide: Allergy and COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | Guide: Allergy and COVID-19 Vaccination 1. Vaccinate without additional precautions Vaccinate in the community as per national recommendations, with a post-vaccination observation period of 15 minutes . This includes people with: History of allergy, including anaphylaxis to food, drugs, venom, or latex. Allergic (...) conditions, including asthma, atopic dermatitis (eczema) or allergic rhinitis (hay fever). 2. Vaccinate with precautions* Immediate (within four hours) and generalised symptoms of a possible allergic reaction without anaphylaxis to a previous dose of a COVID-19 vaccine. Generalised allergic reaction (without anaphylaxis) to one of the ingredients in the COVID-19 vaccine to be administered (Pfizer-PEG or AstraZeneca-Polysorbate 80). Prior history of anaphylaxis to previous vaccines and/or multiple drugs

2021 Australasian Society of Clinical Immunology and Allergy

82. ASCIA COVID-19 vaccine information

to the COVID-19 outbreak many suppliers of medical products are working to ensure the continuity of supply to patients in Australia and New Zealand, whilst also protecting the health of their employees. ASCIA is monitoring the situation and will post notices on this page from medical product suppliers and authorities, including the National Blood Authority (NBA) and the Theraputic Goods Administration (TGA). NBA response to novel coronavirus TGA amendment to restrict hydroxychloroquine prescribing ARRC (...) ASCIA COVID-19 vaccine information ASCIA COVID-19 Information - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | ASCIA COVID-19 Information | | | | | | | | | | | | COVID-19 vaccine information COVID-19 vaccine information: ASCIA New March 2021 New March 2021 New March 2021 New March 2021 Other ASCIA COVID-19 information for patients, consumers, carers is available at COVID-19 vaccine information: AU and NZ Governments COVID-19 vaccination decision guide for women who

2021 Australasian Society of Clinical Immunology and Allergy

83. Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge Key Highlights from the CTS position statement

Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge Key Highlights from the CTS position statement Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge Key Highlights From the Canadian Thoracic Society (CTS) Position Statement Samir Gupta, MD Jane Batt, MD Toronto, ON, Canada Jean Bourbeau, MD Montreal, QC, Canada Kenneth R. Chapman, MD Andrea (...) , Canada Mohit Bhutani, MD Edmonton, AB, Canada Viral pandemics can quickly overwhelm health system capacity. When a rapid increase in patients with coronavirus disease 2019 (COVID-19) led to ICU bed shortages in Northern Italy 1 and elsewhere, clinicians were forced to make dif?cult ICU resource allocation decisions. Similar surges are now being seen in other parts of the world, including the United States. What Frameworks Are Available to Support Resource Allocation Decisions? Ethical frameworks

2021 Canadian Thoracic Society

84. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Full Text available with Trip Pro

prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. - - Guan WJ, Ni ZY, Hu Y, et al. ; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. - - Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4(7):1178-1191. - - Show all 95 references MeSH (...) American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly

2021 EvidenceUpdates

85. Clinical applications of detecting IgG, IgM, or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review Full Text available with Trip Pro

Clinical applications of detecting IgG, IgM, or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Int J Infect Dis Actions . 2021 Jan 12;104:415-422. doi: 10.1016/j.ijid.2021.01.016. Online ahead of print. Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review , , , , , Affiliations Expand Affiliations 1 Department of Otorhinolaryngology, Head and Neck

2021 EvidenceUpdates

86. Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic Full Text available with Trip Pro

Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: 1 selected item: 33525596 - PubMed To: Format: MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collection

2021 EvidenceUpdates

87. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients Full Text available with Trip Pro

Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Sci Rep Actions . 2021 Feb 5;11(1):3246. doi: 10.1038/s41598-021-81844-x. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacology

2021 EvidenceUpdates

88. What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control?

What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? Rebecca E Ryan | Anne Parkhill | Lina Schonfeld | Louisa Walsh | Dianne Lowe | Bronwen Merner | Nami Nelson | Sophie J Hill HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 72 What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control (...) ? World Health Organization Regional Office for Europe UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Tel.: +45 45 33 70 00 Fax: +45 45 33 70 01 Email: eurocontact@who.int Website: www.euro.who.int HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 72Health Evidence Network synthesis report 72 What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? Rebecca E Ryan | Anne Parkhill | Lina Schonfeld

2021 WHO Health Evidence Network

89. COVID-19: investigation and management of suspected SARS-CoV-2 reinfections

COVID-19: investigation and management of suspected SARS-CoV-2 reinfections COVID-19: investigation and management of suspected SARS-CoV-2 reinfections - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional (...) cookies You can at any time. Hide this message Show or hide search Search on GOV.UK Search Menu National lockdown: stay at home Check what you need to do Guidance COVID-19: investigation and management of suspected SARS-CoV-2 reinfections Steps for investigating and managing individuals who are suspected to be reinfected with SARS-CoV-2. From: Published: 15 March 2021 Applies to: England Documents HTML Details This guidance is for clinicians and infection specialists. It provides details

2021 Public Health England

90. Looking back at a year that changed the world: WHO’s response to COVID-19

point in the WHO Western Pacific Regional Office, and within 24 hours WHO had activated its Incident Management Support Team (IMST) across the three levels of the Organization. On 5 January 2020 WHO alerted all Member States to the cluster through the International Health Regulations Event Information System, and several days later reported that the cluster had been caused by the novel coronavirus that we now know as COVID-19. Epidemiological overview: January to December 2020 31 Dec | WHO’s Country (...) Looking back at a year that changed the world: WHO’s response to COVID-19 Looking back at a year that changed the world WHO’S RESPONSE TO COVID-19 22 January 2021iii 22 January 2021 Looking back at a year that changed the world WHO’S RESPONSE TO COVID-19iv Looking back at a year that changed the world: WHO’s response to COVID-19 WHO/WHE/2021.01 © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO

2021 WHO Coronavirus disease (COVID-19) Pandemic

91. Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review

Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review Prescrire IN ENGLISH - Spotlight ''Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review'', 1 March 2021 {1} {1} {1} | | > > > Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review FEATURED REVIEW Very large amounts of data about covid-19 were published over the past year. As they became available, Prescrire sorted through to determine just which data were useful for the treatment and prevention of the disease. Full review (3 pages) available for download by subscribers. Abstract In order to provide high-quality health care, it is useful to continually

2021 Prescrire

92. Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021

Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021 Prescrire IN ENGLISH - Spotlight ''Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021'', 02 March 2021 {1} {1} {1} | | > > > Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021 Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021 COVID-19 The available clinical trial data have led the editors of independent French medical journal Prescrire to assign these vaccines the seldom-granted rating "A Real Advance". As of 2 March 2021 , two messenger ribonucleic acid (mRNA) covid-19 vaccines have been authorised in the European Union: the covid-19 mRNA vaccine BNT162b2, international nonproprietary name (INN

2021 Prescrire

93. COVID-19 and worklessness: support for London local authorities

COVID-19 and worklessness: support for London local authorities COVID-19 and worklessness: support for London local authorities - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional cookies You can at any time (...) . Hide this message Show or hide search Search on GOV.UK Search Menu National lockdown: stay at home Check what you need to do Guidance COVID-19 and worklessness: support for London local authorities This report provides information on worklessness and support available to local authorities to mitigate worklessness locally. From: Published: 19 February 2021 Applies to: England Documents Ref: PHE publications gateway number GW-1948 . Please tell us what format you need. It will help us if you say what

2021 Public Health England

94. SARS-CoV-2 infection, COVID-19 and timing of elective surgery

. Public Health England. COVID-19 infection prevention and control guidance: transmission based precautions (TBPs). 2021. https://www.gov.uk/government/publications/wuhan-novel- coronavirus-infection-prevention-and-control/covid-19-infection-prevention-and-control- guidance-transmission-based-precautions-tbps. (accessed 18/02/2021) 28. Cook TM. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic – a narrative review. Anaesthesia 2020; 75: 920–927. 29. National Institute (...) SARS-CoV-2 infection, COVID-19 and timing of elective surgery SARS-CoV-2 infection, COVID-19 and timing of elective surgery A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Centre for Perioperative Care, Federation of Surgical Specialty Associations, Royal College of Anaesthetists, Royal College of Surgeons of England K. El-Boghdadly, 1,2 T. M. Cook, 3,4 T. Goodacre, 5,6 J. Kua, 7 L. Blake, 8 S. Denmark, 9 S. McNally, 10,11 N. Mercer, 12,13 S. R

2021 ICM Anaesthesia COVID-19

95. Nanoe X Air-E as preventive air treatment device for Covid-19

diseases. 2020 Jun;26(6):1320. 12. Chan J, Yuan S and Kok K et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020 doi: 10.1016/S0140-6736(20)30154-9 13. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. Presumed asymptomatic carrier transmission of COVID-19. Jama. 2020 Apr 14;323(14):1406-7. 14. Huang C, Wang Y and Li X et al. Clinical features of patients infected with 2019 novel (...) coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. 15. Burke RM. Active monitoring of persons exposed to patients with confirmed COVID-19— United States, January–February 2020. MMWR. Morbidity and mortality weekly report. 2020;69. 16. World Health Organisation (WHO). Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Available at: https://www.who.int/news- room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for- ipc

2021 MaHTAS Covid-19 Rapid Evidence Updates

96. Reducing the minimum age for mask wearing requirements and recommendations in COVID-19

Reducing the minimum age for mask wearing requirements and recommendations in COVID-19 Advice to the National Public Health Emergency Team: Reduction of the minimum age for the application of mask wearing requirements and recommendations Health Information and Quality Authority Page 1 of 20 Advice to the National Public Health Emergency Team: Reduction of the minimum age for the application of mask wearing requirements and recommendations Submitted to NPHET: 3 March 2021 Published: 4 March 2021 (...) syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious virus which has caused tens of millions of cases of COVID-19 since its emergence in 2019, with a considerable level of associated mortality. In the context of the ongoing COVID-19 pandemic, SARS-CoV-2 constitutes a significant public health concern due to its high basic reproduction rate, the absence of immunity in the human population, the limited evidence of effective treatment approaches, and the constrained supply of vaccines in the early

2021 Health Information and Quality Authority

97. Using face masks in the community: first update - Effectiveness in reducing transmission of COVID-19

Using face masks in the community: first update - Effectiveness in reducing transmission of COVID-19 Using face masks in the community: first update - Effectiveness in reducing transmission of COVID-19 Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Using face masks in the community: first update - Effectiveness in reducing transmission of COVID-19 Using face masks (...) in the community: first update - Effectiveness in reducing transmission of COVID-19 Technical report 15 Feb 2021 Cite: European Centre for Disease Prevention and Control. Using face masks in the community: first update. 15 February 2021. ECDC: Stockholm; 2021. This technical report reviews the evidence that has been accumulated since the emergence of COVID-19, in addition to what has existed on this topic prior to the pandemic, and updates the ECDC opinion on the suitability of using face masks

2021 European Centre for Disease Prevention and Control - Covid-19 Guidance

98. Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA

Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU (...) /EEA Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA Technical report 17 Feb 2021 Cite: European Centre for Disease Prevention and Control. Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA. 17 February 2021. ECDC: Stockholm; 2021. This Technical Report presents evidence about the current status of Behavioural Insights (BI) research being conducted in the ten EU/EEA Member States

2021 European Centre for Disease Prevention and Control - Covid-19 Guidance

99. NACI rapid response: extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada

NACI rapid response: extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada COVID-19 vaccine extended dose interval for Canadians: NACI recommendation - Canada.ca Language selection Search Search Canada.ca Search Menu Main Menu You are here: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada On this page Preamble The National Advisory Committee (...) of COVID-19 vaccines in preventing various health outcomes such as infection, symptomatic disease, hospitalizations and death from COVID-19. While studies have not yet collected four months of data on vaccine effectiveness after the first dose, the first two months of real world effectiveness are showing sustained high levels of protection. Short term sustained protection is consistent with immunological principles and vaccine science where it is not expected to see rapid waning of a highly effective

2021 CPG Infobase

100. Recommendations for the use of COVID-19 vaccines Full Text available with Trip Pro

The following highlights key, current information for immunization providers on COVID-19 vaccine. The evidence on COVID-19 disease and vaccines is evolving. Evidence from clinical trial data is limited due to limitations in the size and duration of follow-up of trial populations; however, studies are ongoing. NACI will continue to monitor the data and update its recommendations as needed. Please refer to the remainder of the Statement for details. What Disease Novel coronavirus disease 2019 (COVID-19 (...) Recommendations for the use of COVID-19 vaccines Recommendations on the use of COVID-19 vaccines - Canada.ca Language selection Search Search Canada.ca Search Menu Main Menu You are here: Recommendations on the use of COVID-19 vaccines Publication date: March 16, 2021 On this page Table of updates This evergreen document will be updated as COVID-19 vaccines are authorized for use in Canada, and as evidence on these vaccines and COVID-19 evolves. This table summarizes the latest changes

2021 CPG Infobase